Evoke Pharma Inc. (EVOK)
Evoke Pharma Statistics
Share Statistics
Evoke Pharma has 1.49M shares outstanding. The number of shares has increased by -82.47% in one year.
| Shares Outstanding | 1.49M |
| Shares Change (YoY) | -82.47% |
| Shares Change (QoQ) | 81.38% |
| Owned by Institutions (%) | 6.09% |
| Shares Floating | 1.42M |
| Failed to Deliver (FTD) Shares | 2.92K |
| FTD / Avg. Volume | 18.85% |
Short Selling Information
The latest short interest is 38.71K, so 2.61% of the outstanding shares have been sold short.
| Short Interest | 38.71K |
| Short % of Shares Out | 2.61% |
| Short % of Float | 2.73% |
| Short Ratio (days to cover) | 1.25 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is 9.27. Evoke Pharma's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | 9.27 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Evoke Pharma Inc. has an Enterprise Value (EV) of 3.77M.
| EV / Earnings | 0 |
| EV / Sales | 0 |
| EV / EBITDA | 0 |
| EV / EBIT | 0 |
| EV / FCF | 0 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.
| Current Ratio | 1.66 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | -1057795.08 |
| Interest Coverage | 10.38 |
Financial Efficiency
Return on equity (ROE) is -0.76% and return on capital (ROIC) is -73.94%.
| Return on Equity (ROE) | -0.76% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -73.94% |
| Revenue Per Employee | $3,416,471,666,666.67 |
| Profits Per Employee | $-1,784,064,666,666.67 |
| Employee Count | 3 |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -58.59% in the last 52 weeks. The beta is 0.12, so Evoke Pharma's price volatility has been higher than the market average.
| Beta | 0.12 |
| 52-Week Price Change | -58.59% |
| 50-Day Moving Average | 4.39 |
| 200-Day Moving Average | 5.05 |
| Relative Strength Index (RSI) | 25.02 |
| Average Volume (20 Days) | 15.49K |
Income Statement
In the last 12 months, Evoke Pharma had revenue of 10,249.4B and earned -5,352.2B in profits. Earnings per share was -3823317.97.
| Revenue | 10,249.4B |
| Gross Profit | 10,249.4B |
| Operating Income | -5,204.1B |
| Net Income | -5,352.2B |
| EBITDA | -5,204.1B |
| EBIT | -5,204.1B |
| Earnings Per Share (EPS) | -3823317.97 |
Balance Sheet
The company has 13.6M in cash and 5.16M in debt, giving a net cash position of 8.44M.
| Cash & Cash Equivalents | 13.6M |
| Total Debt | 5.16M |
| Net Cash | 8.44M |
| Retained Earnings | -128,791.6B |
| Total Assets | 17.52M |
| Working Capital | 6.86M |
Cash Flow
In the last 12 months, operating cash flow was -5,458.7B and capital expenditures 0, giving a free cash flow of -5,458.7B.
| Operating Cash Flow | -5,458.7B |
| Capital Expenditures | 0 |
| Free Cash Flow | -5,458.7B |
| FCF Per Share | -3899430.09 |
Margins
Gross margin is 100%, with operating and profit margins of -50.77% and -52.22%.
| Gross Margin | 100% |
| Operating Margin | -50.77% |
| Pretax Margin | -52.22% |
| Profit Margin | -52.22% |
| EBITDA Margin | -50.77% |
| EBIT Margin | -50.77% |
| FCF Margin | -53.26% |
Dividends & Yields
EVOK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -127870166.22% |
| FCF Yield | -122856924.22% |
Analyst Forecast
Currently there are no analyst rating for EVOK.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 1, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Aug 1, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -10.15 |
| Piotroski F-Score | 2 |